Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.Napo is conducting a multicenter, randomized double-blind placebo-controlled Phase 2 clinical trial in adult Type 1 short bowel syndrome (SBS) patients without colin-in-continuity.